Links
Tools
Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue.
Journal article published in 2009 by
J. Jendle 
,
M. A. Nauck,
Dr R. Matthews,
A. Frid,
K. Hermansen,
M. Düring,
M. Düring,
M. Zdravkovic,
Bj J. Strauss,
Aj J. Garber
,
M. A. Nauck,
Dr R. Matthews,
A. Frid,
K. Hermansen,
M. Düring,
M. Düring,
M. Zdravkovic,
Bj J. Strauss,
Aj J. Garber
Abstract
AIM: The effect on body composition of liraglutide, a once-daily human glucagon-like peptide-1 analogue, as monotherapy or added to metformin was examined in patients with type 2 diabetes (T2D). METHODS: These were randomized, double-blind, parallel-group trials of 26 [Liraglutide Effect and Action in Diabetes-2 (LEAD-2)] and 52 weeks (LEAD-3). Patients with T2D, aged 18-80 years, body mass index (BMI)